Jim Smithy

melanoma oncologist @mskcancercenter I clinical trials, cellular therapy & translational immunotherapy research | n.b.: personal account

[NBC News @NBCNews]

An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. https://t.co/HM3RcPYkwG

[Jim Smithy @jsmithymd]

*fantastic* PFS data for darovasertib & crizotinib in HLA A 02:01 negative metastatic uveal melanoma —huge step forward in an area with immense unmet need 👏🏼 👏🏼 👏🏼 #ASCO26

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Today at #ASCO26: MSK’s @jsmithymd shared his rapid oral abstract “A phase 2 trial of IO102-IO103 and nivolumab-relatimab in previously untreated, unresectable #melanoma.”

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Join MSK melanoma medical oncologist Dr. @jsmithymd at #ASCO26 as he presents results from a phase 2 trial evaluating IO102-IO103 in combination with nivolumab-relatlimab in patients with previously untreated, unresectable melanoma.

🕒 Saturday, May 30 | 5:36 p.m. CDT

Learn more: https://t.co/icY3htlvVU

[Jim Smithy @jsmithymd]

a translational tour de force covering the last 15 years in melanoma therapy by dr antoni ribas; immense progress but still lots of work to do 🧬 🧫 @MSKCancerCenter

[OncoDaily @oncodaily]

𝗧𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗗𝗮𝘆 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 continues with a series of expert-led sessions and presentations, featuring leading clinicians and researchers who highlight emerging therapies, share real-world clinical insights, and explore strategies to advance early detection and improve outcomes in melanoma care worldwide.

𝗝𝗮𝗺𝗲𝘀 𝗦𝗺𝗶𝘁𝗵𝘆(@jsmithymd) discussed emerging cell therapy platforms for advanced melanoma, highlighting innovative adoptive cell therapies and next-generation immune-based strategies that are expanding treatment possibilities for patients with refractory disease.

𝗭𝘂𝗹𝗳𝗶𝗾𝘂𝗲𝗿 𝗢𝘁𝘁𝘆 reviewed current approaches to first-line therapy of metastatic melanoma, focusing on treatment selection, immunotherapy combinations, and factors guiding personalized management in clinical practice.

𝗔𝘅𝗲𝗹 𝗛𝗮𝘂𝘀𝗰𝗵𝗶𝗹𝗱 shared perspectives on how melanoma is treated across Europe, outlining regional practices, evolving therapeutic standards, and the integration of novel systemic therapies into routine care.

𝗭𝗮𝗵𝗿𝗮 𝗠𝗼𝗵𝗮𝗺𝗲𝗱 𝗔𝗵𝗺𝗲𝗱 explored the challenges encountered when clinical guidelines meet real-world practice, emphasizing practical decision-making, resource considerations, and adapting evidence-based recommendations to diverse patient settings.

More insights continue to emerge as the OncoDaily Global Symposium unfolds 🌍

🔴 Live sessions available here:

https://t.co/4NMZycjfsR

https://t.co/CF3q839sVl

#OncoDaily #Cancer #Oncology

[Jim Smithy @jsmithymd]

@AdamJSchoenfeld @JenWargoMD such a great talk 👏🏼 👏🏼 👏🏼

[Jim Smithy @jsmithymd]

looking forward to a great day of discussion on solid tumor cell therapy at iwCART & sharing updates on PRAME-targeted TCR-T in advanced melanoma

[Jim Smithy @jsmithymd]

@sesamestreet this is very insensitive to Elmo

[JAMA Oncology @JAMAOnc]

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. https://t.co/eMMt4PkB6b

[Jim Smithy @jsmithymd]

@andruyeung is this a joke

[Jim Smithy @jsmithymd]

@johntrified east side to LGA is 30 min

[Jessie (Stuart) Ross, MD @JessieStuart316]

I wrote about the ambiguity in prognosis of a stage IV cancer diagnosis nowadays and the bravery our patients exhibit when they navigate that ambiguity every day. @NEJM

https://t.co/6AaujMRKJw

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Ellen was diagnosed with a rare and hard to treat #ovariancancer. Everything changed when she enrolled in a clinical trial led by Dr. Rachel Grisham, based on a lab discovery years ago by @DSolit.

Watch more #SavedbyScience stories on YouTube: https://t.co/1th60xfrkk

[Jim Smithy @jsmithymd]

@BacardiCapital Philly ⬆️ ⬆️ ⬆️

[Jim Smithy @jsmithymd]

@emmakurz @MSKCancerCenter @MGHMedicine @MSK_DeptOfMed congrats & welcome to MSK!!

[Jim Smithy @jsmithymd]

that’s a wrap on melanoma bridge! three days tackling the most pressing questions in the field with an inspiring roster of speakers… thank you @PAscierto & colleagues for organizing

[Jim Smithy @jsmithymd]

@Chrystal_Paulos @PAscierto congratulations and fantastic talk!! excited to see what’s next for Th17 adoptive cell therapy

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

More than a year after receiving a type of immunotherapy called tumor-infiltrating lymphocyte (#TIL) therapy, Pattie is doing well and has almost no signs of metastatic #melanoma

Learn more from @jsmithymd, a melanoma medical oncologist and cellular therapist at MSK and expert in #TILtherapy.

https://t.co/6UuUHwRDC0

[Jim Smithy @jsmithymd]

@JordanRaanan soooo painful